AB Science (XPAR:AB) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:AB AB Science XPAR:AB
57 GF Score
Price €0.62
GF Value €1.47
Valuation Possible Value Trap
! 11 Warning Signs
View Full Analysis

What is AB Science FFO per Share?

FFO per Share only applies to REITs.

XPAR:AB
57GF Score
AB Science XPAR:AB
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AB Science (XPAR:AB) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of €0.62 is trading 58% below its estimated GF Value™ of €1.47. GuruFocus considers AB Science to be Possible Value Trap.

Key valuation signals for XPAR:AB:

  • FFO per Share:
  • GF Value™: €1.47 vs. price of €0.62 (58% below fair value)
  • GF Score™: 57/100 with 11 warning signs

No single metric tells the full story. See the XPAR:AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Other Exchanges ABSCF:USA0Q77:UKA8D:Germany
Address 3, Avenue George V, Paris, FRA, 75008
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
57GF Score

Get the complete analysis for XPAR:AB

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.62
Price
€1.47
GF Value